share_log

Leerink Partners Upgrades Blueprint Medicines to Market Perform, Raises Price Target to $97

Benzinga ·  May 6 13:47

Leerink Partners analyst Andrew Berens upgrades Blueprint Medicines (NASDAQ:BPMC) from Underperform to Market Perform and raises the price target from $50 to $97.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment